NCT01066663View on ClinicalTrials.gov

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

February 28, 2022

Study Completion Date

January 31, 2023

Conditions
Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia
Interventions
DRUG

pyrimethamine

Taken orally once a day

Trial Locations (2)

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Lymphoma Research Foundation

OTHER

lead

Dana-Farber Cancer Institute

OTHER